Redeye comments on today’s news where Dignitana has engaged a medical device and a market access specialist to push the reimbursement process further. We see these two new partners as a positive sign and will help establish reimbursement at the correct levels. We are encouraged to see these steps taken by Dignitana as we see reimbursement as one of the important factors that could drive long-term growth in the US. Therefore, we reiterate our base case fair value of SEK 16 per share.